{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T18:22:56Z","timestamp":1787682176154,"version":"build-2784847793"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:00:00Z","timestamp":1696982400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001631","name":"University College Dublin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001631","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002714","name":"Albert-Ludwigs-Universit\u00e4t Freiburg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002714","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010890","name":"Central People's Government of the People's Republic of China Scholarship Programme","doi-asserted-by":"publisher","award":["CSC202008300001"],"award-info":[{"award-number":["CSC202008300001"]}],"id":[{"id":"10.13039\/501100010890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001602","name":"Science Foundation Ireland","doi-asserted-by":"publisher","award":["19\/FFP\/6522"],"award-info":[{"award-number":["19\/FFP\/6522"]}],"id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Methods & Clinical Development"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.omtm.2023.101134","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T02:37:01Z","timestamp":1697164621000},"page":"101134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["CRISPR-Cas9-based non-viral gene editing therapy for topical treatment of recessive dystrophic epidermolysis bullosa"],"prefix":"10.1016","volume":"31","author":[{"given":"Xianqing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigen","family":"A","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albina","family":"Bushmalyova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonglei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8702-3859","authenticated-orcid":false,"given":"Irene","family":"Lara-S\u00e1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2023.101134_bib1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41572-020-0210-0","article-title":"Epidermolysis bullosa","volume":"6","author":"Bardhan","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.omtm.2023.101134_bib2","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s11136-020-02495-5","article-title":"Quality of life in people with epidermolysis bullosa: a systematic review","volume":"29","author":"Togo","year":"2020","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.omtm.2023.101134_bib3","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13023-021-01811-7","article-title":"A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa","volume":"16","author":"Tang","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.omtm.2023.101134_bib4","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41591-022-01737-y","article-title":"In\u00a0vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial","volume":"28","author":"Gurevich","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2023.101134_bib5","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1038\/jid.2012.11","article-title":"siRNA-Mediated Allele-Specific Inhibition of Mutant Type VII Collagen in Dominant Dystrophic Epidermolysis Bullosa","volume":"132","author":"Pendaries","year":"2012","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.omtm.2023.101134_bib6","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.jid.2020.08.018","article-title":"QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study","volume":"141","author":"Bornert","year":"2021","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.omtm.2023.101134_bib7","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1016\/j.jid.2016.07.029","article-title":"Targeted Exon Skipping Restores Type VII Collagen Expression and Anchoring Fibril Formation in an In\u00a0Vivo RDEB Model","volume":"136","author":"Turczynski","year":"2016","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.omtm.2023.101134_bib8","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/gt.2016.57","article-title":"Construction and validation of an RNA trans-splicing molecule suitable to repair a large number of COL7A1 mutations","volume":"23","author":"Tockner","year":"2016","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2023.101134_bib9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1034\/j.1600-0625.2003.120105.x","article-title":"Development of spliceosome-mediated RNA trans-splicing (SMaRT\u2122) for the correction of inherited skin diseases","volume":"12","author":"Dallinger","year":"2003","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.omtm.2023.101134_bib10","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jid.2015.11.028","article-title":"Meganuclease-Mediated COL7A1 Gene Correction for Recessive Dystrophic Epidermolysis Bullosa","volume":"136","author":"Izmiryan","year":"2016","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.omtm.2023.101134_bib11","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/mt.2013.56","article-title":"TALEN-based Gene Correction for Epidermolysis Bullosa","volume":"21","author":"Osborn","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.101134_bib12","doi-asserted-by":"crossref","first-page":"e307","DOI":"10.1038\/mtna.2016.19","article-title":"Gene Editing for the Efficient Correction of a Recurrent COL7A1 Mutation in Recessive Dystrophic Epidermolysis Bullosa Keratinocytes","volume":"5","author":"Chamorro","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtm.2023.101134_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2023.100191","article-title":"Cytosine deaminase base editing to restore COL7A1 in dystrophic epidermolysis bullosa human:murine skin model","volume":"3","author":"Naso","year":"2023","journal-title":"JID Innov."},{"key":"10.1016\/j.omtm.2023.101134_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-24184-8","article-title":"ABE8e adenine base editor precisely and efficiently corrects a recurrent COL7A1 nonsense mutation","volume":"12","author":"Sheriff","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtm.2023.101134_bib15","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1016\/j.ymthe.2022.06.005","article-title":"Therapeutic base editing and prime editing of COL7A1 mutations in recessive dystrophic epidermolysis bullosa","volume":"30","author":"Hong","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.101134_bib16","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.omtm.2022.09.005","article-title":"Preclinical model for phenotypic correction of dystrophic epidermolysis bullosa by in\u00a0vivo CRISPR-Cas9 delivery using adenoviral vectors","volume":"27","author":"Garc\u00eda","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2023.101134_bib17","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.omtn.2021.05.015","article-title":"A non-viral and selection-free COL7A1 HDR approach with improved safety profile for dystrophic epidermolysis bullosa","volume":"25","author":"Kocher","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtm.2023.101134_bib18","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.ymthe.2021.02.019","article-title":"Correction of recessive dystrophic epidermolysis bullosa by homology-directed repair-mediated genome editing","volume":"29","author":"Bonafont","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.101134_bib19","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1016\/j.jid.2020.02.012","article-title":"Predictable CRISPR\/Cas9-Mediated COL7A1 Reframing for Dystrophic Epidermolysis Bullosa","volume":"140","author":"Kocher","year":"2020","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.omtm.2023.101134_bib20","doi-asserted-by":"crossref","first-page":"7409","DOI":"10.1021\/acs.chemrev.7b00678","article-title":"Intracellular Delivery by Membrane Disruption: Mechanisms, Strategies, and Concepts","volume":"118","author":"Stewart","year":"2018","journal-title":"Chem. Rev."},{"key":"10.1016\/j.omtm.2023.101134_bib21","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/molecules23113044","article-title":"A Review on Electroporation-Based Intracellular Delivery","volume":"23","author":"Shi","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.omtm.2023.101134_bib22","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nm0595-481","article-title":"Gene gun and other non-viral approaches for cancer gene therapy","volume":"1","author":"Yang","year":"1995","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2023.101134_bib23","series-title":"Microinjection Methods in Molecular Biology","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-8831-0_1","article-title":"Microinjection and Micromanipulation: A Historical Perspective","author":"Xu","year":"2019"},{"key":"10.1016\/j.omtm.2023.101134_bib24","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1039\/D1BM01452H","article-title":"Pre-clinical non-viral vectors exploited for in\u00a0vivo CRISPR\/Cas9 gene editing: an overview","volume":"10","author":"Rouatbi","year":"2022","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.omtm.2023.101134_bib25","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1208\/s12248-021-00608-7","article-title":"Non-viral Vectors in Gene Therapy: Recent Development, Challenges, and Prospects","volume":"23","author":"Zu","year":"2021","journal-title":"AAPS J."},{"key":"10.1016\/j.omtm.2023.101134_bib26","doi-asserted-by":"crossref","first-page":"5316","DOI":"10.1021\/ja034429c","article-title":"Parallel Synthesis and Biophysical Characterization of a Degradable Polymer Library for Gene Delivery","volume":"125","author":"Akinc","year":"2003","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.omtm.2023.101134_bib27","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jconrel.2023.01.002","article-title":"Recent progress and applications of poly(beta amino esters)-based biomaterials","volume":"354","author":"Wei","year":"2023","journal-title":"J.\u00a0Contr. Release"},{"key":"10.1016\/j.omtm.2023.101134_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113842","article-title":"Highly branched poly(\u03b2-amino ester)s for gene delivery in hereditary skin diseases","volume":"176","author":"Zeng","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omtm.2023.101134_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1600102","article-title":"The transition from linear to highly branched poly(\u03b2-amino ester)s: Branching matters for gene delivery","volume":"2","author":"Zhou","year":"2016","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omtm.2023.101134_bib30","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jconrel.2016.06.014","article-title":"Highly branched poly(\u03b2-amino ester)s for skin gene therapy","volume":"244","author":"Zhou","year":"2016","journal-title":"J.\u00a0Control Release."},{"key":"10.1016\/j.omtm.2023.101134_bib31","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1365-2133.2012.11128.x","article-title":"Recessive dystrophic epidermolysis bullosa: the origin of the c.6527insC mutation in the Spanish population: Correspondence","volume":"168","author":"Sanchez-Jimeno","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.omtm.2023.101134_bib32","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.omtn.2018.01.009","article-title":"Deletion of a Pathogenic Mutation-Containing Exon of COL7A1 Allows Clonal Gene Editing Correction of RDEB Patient Epidermal Stem Cells","volume":"11","author":"Menc\u00eda","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtm.2023.101134_bib33","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.ymthe.2019.03.007","article-title":"Clinically Relevant Correction of Recessive Dystrophic Epidermolysis Bullosa by Dual sgRNA CRISPR\/Cas9-Mediated Gene Editing","volume":"27","author":"Bonafont","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.101134_bib34","doi-asserted-by":"crossref","first-page":"e379","DOI":"10.1038\/mtna.2016.87","article-title":"Antisense Oligonucleotide-mediated Exon Skipping as a Systemic Therapeutic Approach for Recessive Dystrophic Epidermolysis Bullosa","volume":"5","author":"Bremer","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtm.2023.101134_bib35","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/mt.2016.92","article-title":"Analysis of the functional consequences of targeted exon deletion in COL7A1 reveals prospects for dystrophic epidermolysis bullosa therapy","volume":"24","author":"Bornert","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.101134_bib36","doi-asserted-by":"crossref","first-page":"24429","DOI":"10.1074\/jbc.M003440200","article-title":"Development and Characterization of A Recombinant Truncated Type VII Collagen \u201cMinigene","volume":"275","author":"Chen","year":"2000","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtm.2023.101134_bib37","doi-asserted-by":"crossref","first-page":"30661","DOI":"10.1021\/acsami.9b13135","article-title":"Efficient and Robust Highly Branched Poly(\u03b2-amino ester)\/Minicircle COL7A1 Polymeric Nanoparticles for Gene Delivery to Recessive Dystrophic Epidermolysis Bullosa Keratinocytes","volume":"11","author":"Zeng","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.omtm.2023.101134_bib38","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.omtm.2023.101134_bib39","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/bjd\/ljac001","article-title":"Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study","volume":"188","author":"Kern","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.omtm.2023.101134_bib40","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.omtn.2018.06.008","article-title":"Ex\u00a0Vivo COL7A1 Correction for Recessive Dystrophic Epidermolysis Bullosa Using CRISPR\/Cas9 and Homology-Directed Repair","volume":"12","author":"Izmiryan","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtm.2023.101134_bib41","doi-asserted-by":"crossref","first-page":"26846","DOI":"10.1073\/pnas.1907081116","article-title":"CRISPR\/Cas9-based targeted genome editing for correction of recessive dystrophic epidermolysis bullosa using iPS cells","volume":"116","author":"Jack\u00f3w","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2023.101134_bib42","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.omtn.2019.09.011","article-title":"Improved Double-Nicking Strategies for COL7A1-Editing by Homologous Recombination","volume":"18","author":"Kocher","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtm.2023.101134_bib43","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.tcb.2020.01.004","article-title":"Prime Editing: A New Way for Genome Editing","volume":"30","author":"Marzec","year":"2020","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.omtm.2023.101134_bib44","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.jid.2019.02.015","article-title":"Efficient Gene Reframing Therapy for Recessive Dystrophic Epidermolysis Bullosa with CRISPR\/Cas9","volume":"139","author":"Takashima","year":"2019","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.omtm.2023.101134_bib45","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1073\/pnas.1614775114","article-title":"Efficient in\u00a0vivo gene editing using ribonucleoproteins in skin stem cells of recessive dystrophic epidermolysis bullosa mouse model","volume":"114","author":"Wu","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2023.101134_bib46","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/jcb.22328","article-title":"The influence of innate and pre-existing immunity on adenovirus therapy","volume":"108","author":"Zaiss","year":"2009","journal-title":"J.\u00a0Cell. Biochem."},{"key":"10.1016\/j.omtm.2023.101134_bib47","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune Responses to Viral Gene Therapy Vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.101134_bib48","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1089\/hum.2010.245","article-title":"Optimizing Promoters for Recombinant Adeno-Associated Virus-Mediated Gene Expression in the Peripheral and Central Nervous System Using Self-Complementary Vectors","volume":"22","author":"Gray","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2023.101134_bib49","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41434-021-00282-6","article-title":"Non-viral delivery of CRISPR\u2013Cas9 complexes for targeted gene editing via a polymer delivery system","volume":"29","author":"O\u2019Keeffe Ahern","year":"2022","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2023.101134_bib50","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.matbio.2016.07.009","article-title":"Molecular pathology of the basement membrane zone in heritable blistering diseases","volume":"57\u201358","author":"Uitto","year":"2017","journal-title":"Matrix Biol."},{"key":"10.1016\/j.omtm.2023.101134_bib51","article-title":"Microfluidic Nanoparticles for Drug Delivery","volume":"18","author":"Liu","year":"2022","journal-title":"Small"},{"key":"10.1016\/j.omtm.2023.101134_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114197","article-title":"Microfluidic fabrication of lipid nanoparticles for the delivery of nucleic acids","volume":"184","author":"Prakash","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omtm.2023.101134_bib53","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jconrel.2015.10.049","article-title":"Nanoparticles and nanofibers for topical drug delivery","volume":"240","author":"Goyal","year":"2016","journal-title":"J.\u00a0Control Release."},{"key":"10.1016\/j.omtm.2023.101134_bib54","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jconrel.2022.07.006","article-title":"Topical formulation based on disease-specific nanoparticles for single-dose cure of psoriasis","volume":"349","author":"Mai","year":"2022","journal-title":"J.\u00a0Control Release."},{"key":"10.1016\/j.omtm.2023.101134_bib55","article-title":"Generation of rabbit polyclonal human and murine collagen VII monospecific antibodies: A useful tool for dystrophic epidermolysis bullosa therapy studies","volume":"4","author":"Bornert","year":"2019","journal-title":"Matrix Biol."}],"container-title":["Molecular Therapy Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050123001730?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050123001730?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T15:23:03Z","timestamp":1762615383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050123001730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":55,"alternative-id":["S2329050123001730"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2023.101134","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CRISPR-Cas9-based non-viral gene editing therapy for topical treatment of recessive dystrophic epidermolysis bullosa","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2023.101134","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"101134"}}